Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.

MLA

Xi, Yaming, et al. “Efficacy, Safety and Bioequivalence of the Human-Derived B-Domain-Deleted Recombinant Factor VIII TQG202 for Prophylaxis in Severe Haemophilia A Patients.” Haemophilia : The Official Journal of the World Federation of Hemophilia, vol. 28, no. 6, Nov. 2022, pp. e219–27. EBSCOhost, https://doi.org/10.1111/hae.14652.

APA

Xi, Y., Jin, C., Liu, W., Zhou, H., Wang, Z., Zhou, R., Lou, S., Zhao, X., Chen, F., Cheng, P., Sun, Z., Jia, H., & Zhang, L. (2022). Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients. Haemophilia : The Official Journal of the World Federation of Hemophilia, 28(6), e219–e227. https://doi.org/10.1111/hae.14652

Chicago

Xi, Yaming, Chenghao Jin, Wei Liu, Hu Zhou, Zhen Wang, Rongfu Zhou, Shifeng Lou, et al. 2022. “Efficacy, Safety and Bioequivalence of the Human-Derived B-Domain-Deleted Recombinant Factor VIII TQG202 for Prophylaxis in Severe Haemophilia A Patients.” Haemophilia : The Official Journal of the World Federation of Hemophilia 28 (6): e219–27. doi:10.1111/hae.14652.